Navigation Links
GPhA Statement on FTC Roundtable on Biogenerics

ARLINGTON, Va., Nov. 21 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the Federal Trade Commission (FTC) roundtable on "Emerging Health Care Competition and Consumer Issues."

"The mere fact that the FTC is conducting this roundtable demonstrates the growing momentum behind ensuring that consumers have access to safe and affordable biogenerics sooner rather than later. As our elected officials grapple with issues like market exclusivity and patent resolution measures, they must do so recognizing that competition will unleash innovation, while at the same time assuring that affordable lifesaving medicines are available for patients in need.

There is no doubt that a sound balance must be struck between innovation and competition in any truly workable biogenerics legislation. This is why GPhA has consistently stated that Hatch-Waxman serves as a reliable model for achieving this shared goal. Hatch-Waxman has been extremely successful for the brand industry, the generic industry, and most importantly, consumers.

We applaud the FTC and Commissioner Pamela Jones Harbour for their forward-looking leadership in addressing the critical issues of competition and innovation in the biopharmaceutical sector. The generic industry agrees with FTC's position, as stated in its May letter to the House Energy & Commerce Committee, that Congress 'should limit companies' ability to game ... exclusivities at the expense of consumers by ... ensuring there is no opportunity for brands effectively to lengthen their exclusivities through insignificant changes to a branded biologic product or through excessive procedural delays.'

2009, the 25th Anniversary of the Hatch-Waxman Act, can be the year when the new Administration and Congress can truly increase access to affordable health care by passing landmark biogenerics legislation. We are committed to working with President-Elect Obama and all members of Congress to ensure that safe and affordable biogeneric medicines get to patients in need in a timely fashion."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 65% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs. For more information about the industry, visit

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Nurotron Biotechnology ... in its largest order to date. , The order will be from the ... Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults suffering ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Amanda Beard and Brooke Bennett are collaborating with brands across various categories through ... four influential figures make up an elite group of Gold Medal Moms who ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Dale Jones as a 2015-2016 inductee into its ... for leadership in education. NAPW is the nation’s leading networking organization exclusively for ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Research Foundation (Meso Foundation) released information for caregivers and held two webinars on ... are available on demand free of charge at . , With ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... --> --> According to ... (Soft Tissue, All Tissue, Dental Welding Lasers), Application (Conservative Dentistry, ... Global Forecast to 2020", published by MarketsandMarkets, is expected to ... 5.2% during the forecast period from 2015 to 2020. ... spread through 167 P ages and in-depth TOC on ...
(Date:11/30/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), a clinical-stage ... delivery systems, announced today it has signed definitive licensing ... of Technologies Co., Ltd. ("HTIT") for exclusive rights to ... China , Hong Kong ... signed at the Israel Knesset (Parliament). ...
Breaking Medicine Technology: